Search results
Results from the WOW.Com Content Network
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Swiss drug major Novartis AG (NYSE: NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as the U.S. Court of ...
Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to ...
Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. [83] [84] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups ...
A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially paving the way for introduction of ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
In 2017, the ABX patent was also acquired by Endocyte [16] and Endocyte together with the above two sets of patents was acquired by Novartis in 2018. [17] Efficacy and safety was initially investigated as a compassionate access treatment in Germany with high tumor targeting and low doses to normal organs. [18]
For premium support please call: 800-290-4726 more ways to reach us